Indication intelligence, analysis and sector perception

Ocata Therapeutics (OCAT) HMCTM cell therapy in a large animal model achieves evidence of remission in Crohn’s Disease - HOLD

September 22, 2015 10:27am

OCAT closed at $4.77 and is UP +$0.02 in an early day’s range of $4.68 to $4.94 on 150 K share volume <3 moth average = 518.1 k shares>

In regard to an article reported in Regenerative Medicine; OCAT has used its proprietary hemangio-derived mesenchymal cell (HMCTM) technology to treat dogs with canine anal furunculosis (CAF), which shares many features with Crohn's disease.

Canines have a physiology and sophisticated immune system that closely resembles that of humans, and canines are the only species that naturally develop symptoms and pathology similar to human fistulizing Crohn's disease, including recurrent fistula activity, a difficult-to-treat manifestation of this chronic inflammatory bowel disorder.

The Bottom Line: OCAT treated six canines that were refractory to standard treatment, including cyclosporine therapy, and all of the canines were found to be completely free of fistulas at three months post-injection. This study provides “evidence” of the safety and therapeutic potential of human pluripotent stem cell-derived mesenchymal stem cells in a large animal model

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.